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1INTRODUCTION
Urolithiasis is a very common problem, and the challenges that it
has posed has been instrumental in devising various means to tackle the
stone burden. With the advent of technology every passing day has seen
innovations that has lead to better stone clearance in every individual
patient.
Since the time H Young1 had attempted his first cystoscopy,
efforts were always being made to access the urinary tract efficiently
and with lesser morbidity as possible. The inventions like semirigid and
flexible ureteroscopes all of which, were an extension of the technology
available at the time like rod lens system and fibre-optics systems. 2, 3
With better access, visualization and stone fragmenting
techniques, endourological procedures have become a mainstay in
treatment of stone diseases. As with advances in vogue at that time,
ureteric stents have undergone dynamic evolution in a constant search
for the ideal design and material and in a bid to surpass or in the least
reduce the symptoms associated with it.
Despite the vast evidence supporting non stented
ureteroscopies,4 worldwide many urologists still prefer to place stents in
2majority of uncomplicated stone removal procedures in a bid to improve
drainage ,stone clearance and clear residual fragments and avoid ureteric
stricture.
Ureteric stents are associated with a wide spectrum of
symptoms thereby producing considerable morbidity ranging from 80 to
98% and the discomfort caused varies from patient to patient.4,5
The symptoms produced by the stent are predominantly
irritative in nature and seems to produce significant bother so as to
affect the quality of life of the patient, warranting removal in some
cases.5,6
An important factor for the stent-related symptoms is the
pressure transmitted to the renal pelvis during urination and trigonal
irritation by the intravesicular part of the stent. Reflux of urine into the
upper tract is inevitable with a patent stent in position and around 80%
of patients were observed to have reflux during voiding stage and this
produces flank pain.5,6
Alpha adrenergic receptor like α1A and α1D have been
documented to be distributed the in the lower urinary tract and the distal
ureter and the use of alpha adrenergic receptor blockers like Tamsulosin
3have shown considerable promise in treating the stent related
symptoms.7,8,9
Hence this study, was done in an effort to determine the effect
of Tamsulosin in improving double-J stent related symptoms and quality
of life following ureteral stent placement.10
4AIM OF THE STUDY
1) To evaluate ureteric stent related morbidity.
2) To evaluate the effect of Tamsulosin in ureteral stent related
morbidity.
5REVIEW OF LITERATURE
Evolution and History of the Double-J stent:
Introduction
Dr. Gustavẽ Simon was the first person to describe inserting a
tubular inert material into the ureter an earliest version of the ureteric
stent in the 1800s. Later in the early 1900s Dr.Joaquin Albarrano made a
catheter exclusively for this purpose, which was made of fabric and
completely coated with lacquer varnish.11
In 1967, Dr.Paul Zimskind and his associates reported about the
use of a straight tube which was open ended and made of silicone which
was used to relieve ureteric obstruction , and referred to it as the
“ureteral splint”. This was the first ever description of a stent being
placed endoscopically unlike the open approach which was being
practised earlier. This marked the modern era in the history of the
ureteral stents. But there was one major problem faced with this stent is
it prone to spontaneously slip out due to its straight nature.12
Various modification in the design of stent were tried to prevent
its migration. Marmar in 1970 closed the proximal end to aid in its
placement, thereby introducing it over a guide-wire by passing it
through a cystoscope.13
6Later in 1973, Orikasa developed the pusher which helped in
placing the stent over a guide-wire. Once placed the main problem was
in maintaining the stent position.14
Gibbons stent in 1974 was the earliest one to address this issue ,
by having numerous barb like like projections along the silicone shaft
with a distal flange. Though it provided effective and adequate drainage
the barbs increased the total diameter to around 11Fr, hence making
placement difficult along narrow obstructed areas.15
Then in 1973 the term stent was added to the vocabulary of
urologists , by Dr.James Montie ,referring to the indwelling tubes that
were placed in the urinary tract.11
In 1974 McCullough introduced the “shepherds crook” stent
that was designed to prevent the slipping out, a design that was
extensively resourced in from stents that were used in vascular surgery
at those times meant for stenting blood vessels. Though the curl in the
upper part prevented the downward migration, still the upward
migration was the problem to contend with.16
In 1978 Dr.Roy P.Finney was the person who described the
existing double J stent which had curls at both ends in opposing
7directions. These curls provided the necessary fixity to these stents
which prevented migration in either direction.17
Modern stents have a full curl in place of just a “j” curl and
are called “pigtails” but the term double-j is still used commonly.18
In 1989 ACMI launched the Magnetip double J stent which
could be removed by a magnet, obviating the need for a cystoscopy. But
it ceased to be used because the Magnetriever used to remove it was not
always reliable and often needed cystoscopy for removing.19
Boston Scientific in 2000 based introduced the Percuflex tail
stent with an aim to decrease the plastic content which was thought to
have caused the patient discomfort. Though Dunn’s study concurred
with this idea, Lingeman in 2009 found no difference of symptoms at
the 4th post operative day.20
Again in 2001 Boston scientific made a stent which had a
firmer upper end to facilitate introduction and a soft lower end so as to
decrease symptom related to the stent but was proved by Davenport in
2011 as no better than the other earlier available stents.21
1n 2006 Cook devised the Resonance metallic stent made of
metal in the form of a continuos coil, appearing like a tight spring. It
8was designed stronger and to have curls at either ends so as to prevent
kinking or collapse inwardly due to extrinsic pressure causing
compression. It is most commonly used in conditions like cervical or
colonic cancer which cause ureteric obstruction. 22
9Earlier until 1978 stents were fashioned to be passable only
endoscopically in a retrograde method, but not suitable for usage during
open procedures.
An ideal stent which was of uniform diameter, passable
through a cystoscope ,urethra and ureteric orifice in either direction, and
did not migrate in both directions, producing less trauma to endothelial
surfaces and radio-opaque to facilitate visualization during fluoroscopy
was needed. Last and foremost is that it had to be made of a material
that had minimal encrustation properties.20
The double J stent made of fine strand tubing of silicone
which curled at either end to form J like hooks were devised. This
solved the problem of migration and due to minimal contact with the
luminal endothelial surfaces produced less discomfort . 23
STENT CHARACTERISTICS :
Initially was available in diameter calibres of 7 and 8.5
Fr and various lengths like 16, 26 and 28cm. It was along the straight
segment of a ureteral stent that the length was measured in between both
the curls. Drainage holes are located at increments of 1cm ; at every
5cm increment standard markings are mentioned on the main shaft.17
10
Earlier ureteral catheters were made from various materials, but
in 1839 vulcanization lead to the development of rubber based catheters
which were firm , flexible and durable. In late 1800s, gum elastic
catheters had been invented in France. By the beginning of 1930s, they
were made of gum elastic which incorporated varnish coated woven
nylon, and were in widespread use. Subsequently they were made of
polyethylene or polyvinyl hence making them a more rigid , facilitating
easy placement.23,24
Stents made of silicone elastomer, a substance having a
consistency similar to that of latex rubber, had the added advantages like
improved elasticity useful for easy placement, maintenance in the proper
position, and increased resistance to encrustation due to urinary deposits.
Silicone has become the standard against which other materials were
measured for tissue compatibility, and was being preferred for urinary
drainage tubes and other forms of self-retaining catheters.23,24
STATE OF THE ART :
Over the period of years various attempts that were made to
improve on the design of the basic Double-J, till recent times have met
with limited success. The basic design of the Double-J has been
excellent in its efficacy. But the silicone rubber, though an excellent
11
material, needs much improvement. Silicone is soft and non-irritating,
hence increases patient comfort, mainly for long-term usage. But
because it has a higher coefficient of friction than the other available
materials, there is increased difficulty during initial passage.24
More-over it is less resistant to encrustation if bacteriuria is present.25
Alternative materials, like thermoplastic elastomers
comprising of polyurethane and other similar compounds— were
available for several years. These materials have varying degrees of
stiffness and, when designed into a more rigid stent, passage over a
guide-wire is easily facilitated. Stents made of elastomers like
polyurethane have walls that are thinner than silicone stents, hence
providing larger lumens with the same outer diameter and, thereby , a
higher capacity for urine drainage. But the other associated properties of
thermoplastic elastomers makes these materials less resistant than
silicone to encrustation. So this characteristic along with the degree of
stiffness, causes more irritation to the luminal mucosa when left
indwelling for long periods.26
New materials and their hydrophilic coatings on both the
external and/or internal stent surface aid to increase long-term lubricity,
which is highly preferred . Any stent which is slick and smooth reduces
12
surface friction greatly, allowing for easier passage over the guidewire
and facilitates proper positioning.27
Other design enhancements which were made include
(a) composite stents (dual durometer), that had a firm proximal curl for
retention in the renal pelvis with a soft distal curl in the bladder which
aids in easy placement and increases patient comfort;
(b) new thermo-sensitive materials, which will be stiff initially
allowing for rapid and easy placement and later softens at body
temperature thus ensuring patient comfort; and
(c) stents with new curl designs and various length configurations that
has the advantage of better retention and decreased proximal
migration.28,29
Despite all these advances, the original concept of the ureteral
stent has not changed much since its inception and the Double-J stent
has maintained its widespread appeal over the years. In a relatively short
time the Double-J has been the impetus for numerous refinements in
procedural techniques and has made a significant impact on the
management of stone disease and other endourological disorders.28
13
Various natural ,synthetic elastomers and biodegradable and
non-biodegradable plastics have been utilized as materials for
endourological catheters and stents. Styrenic thermoplastic elastomers
like e.g. C-Flex, polysiloxanes and olefinic block co-polymers, e.g.
Percuflex, are in general the most preferable non-degradable polymers
available for endourological applications till date. Advances in polymer
chemistry and surface science have created new pathways for potential
improvement of existing materials and the production of new ones
despite their limitations. It is becoming increasingly clear that through
advances in surface grafting and new material formulation, the next
generation of endourological materials on the horizon will emerge with
superior long-term implant characteristics.
Glycosaminoglycan-coated stents were developed in bid to
resist encrustation and prolong the duration of stenting safely, but failed
to garner wider use. 30,31
A modified design of the Tail StentTM model was introduced
with the aim to minimize irritative symptoms of the bladder . This stent
had a proximal pigtail that was of 7 Fr and the shaft that tapered down
to a straight tail of 3Fr diameter without a lumen ,that lies in the
bladder. They were found to produce lesser irritative symptoms than the
standard 7F double J stents in a randomized single-blind trial involving
60 patients.32,33
14
Sof-CurlTM and the PolarisTM stents are the available models of the
Dual-durometer stents which at the renal end has a firm bio-material and
gradually transitions to a softer end in the bladder end thereby reducing
the mechanical irritation of the bladder urothelium.. They are coated
with hydrogel that decreases their friction coefficients . 32,33
INDICATIONS FOR STENTING THE URETER
Stenting of the ureters are done to relieve obstruction of the
ureters and to facilitate the flow of urine. Obstruction may be due to
various causes like stones , papillary necrosis etc. The stents may have
both ends or one end closed. The flow of urine in the ureter is usually
around the stent where it acts as a scaffolding. The various indications
are34
1. Extrinsic obstruction caused by tumors and retroperitoneal fibrosis.
2. Intrinsic obstruction due to stones, stricture or tumors.
In both above scenarios stenting may form either a temporary form
of treatment where definitive treatment is being carried out or it may be
the primary modality of treatment where definitive treatment is not
possible, in situations like
a) bilateral ureteric obstruction
15
b) Single kidney status
c) Intractable renal colic .
d) Unrelievable ureteric obstruction.
There are many emergency situations which need stenting like
ureteric obstruction when it is accompanied with signs of infection (like
pyrexia, pyuria and leucocytosis).
During performing percutaneous procedures for stone removal,
stenting is necessitated in the following instances like35,36
a) When there is perforation of the collecting system
b) In cases where stone burden is more, there may be need for for
adjunctive treatment like extracorporeal shock wave lithotripsy
c) Obstruction of the ureter caused by edema
d) Concomitant pelviureteric junction obstruction
e) If stone fragments migrate into the upper ureter
f) Persistent urinary fistula after nephrostomy tube removal.
After ureterorenoscopy for stone disease, stenting is necessary
in the following cases34 :
16
A) Stone impaction
B) Transient ureteral edema following the procedure which needs to
be bypassed.
C) Stents also cause passive dilatation the ureter , hence aiding in
passage of the residual stone fragments
D) Prevents stricture formation
E) Incomplete stone fragmentation
F) If concomitant prior ureteral dilatation is done.
G) Perforation of the ureter during the procedure
Stenting is also done in other situations like
A) After endopyelotomy, endoureterotomy to prevent stricture
forrnations
B) In cases of urinary extravasation following perforation of the
collecting system or ureter.
C) Prior to extracorporeal shock wave lithotripsy if stone size is
greater than 2 cm and for management of steinstrasse.
17
D) To avoid iatrogenic injury during surgery by identifying the
ureter.
E) Fistulas of the upper urinary tract due to a renal or ureteral origin
F) To relieve the retroperitoneal urinomas that occur after open or
blunt trauma.
G) Obstructive pyelonephritis
H) Renal failure secondary to ureteral obstruction
I) Solitary kidney
J) Transplant kidney
Relative indication :
A) Pregnancy35
B) Long-standing impacted stone
C) Recent history of urinary tract infection or sepsis
D) Passive dilation of ureteral orifice and ureter
E) Prolonged endoscopic operative time
F) Patients with imminent post operative plans (2nd look)
18
PROCEDURE OF STENTING :
Ureteral stenting can be achieved either by retrograde or
ante-grade approach. The retrograde approach is most commonly
employed using either a cystoscope or an ureteroscope. While using a
retrograde approach guide-wires and fluoroscopy are mandatory
irrespective of whether a rigid or flexible cystoscopy is used. Initially
the guide-wire is passed into the desired ureteric orifice under
cystoscopic guidance. Later a stent is advanced over the guide-wire with
the aid of a pusher into the ureter through the ureteric orifice and placed
at the level of the renal pelvis. Advancement of the stent is monitored
using fluoroscopy. Then the stent is allowed to curl in the bladder when
the pusher becomes visible at the bladder neck level, by means of
carefully removing the guide-wire. 37,38
STENT RELATED COMPLICATIONS:
Stent discomfort affects over 80% of patients and can vary
from one individual to another in an idiosyncratic manner.39,40
The symptoms related to ureteral stents are irritative voiding
symptoms including frequency (50-60%), urgency (57-60%), dysuria
(30-40%), incomplete emptying (76%), flank (20-30%) and suprapubic
pain (30%), incontinence, and hematuria (20-25%) are included.41,42,43,44
19
Frequency is caused by the bladder coil which acts as a
mechanical stimulus. Together with urgency, it bothers significant
proportion of patients (60%). Daytime frequency differentiated by the
lack of concomitant nocturia suggests that mechanical stimulation is
related to physical activity and/or awareness of this stimulation during
the day, which may not be felt during the night. Recently, investigators
confirmed that when a stent gets displaced with physical activity that
may cause stent discomfort. 45,46
Urgency is found to be associated directly to the presence of the
stent, which may also unveil or exacerbate underlying pre-existing
subclinical detrusor overactivity.45
Dysuria is commonly experienced at the end of the voiding.
Hence it has been put forth that dysuria is caused due to trigonal
irritation by the lower end of the stent and more so when it crosses the
midline or when it forms an incomplete loop. Trials have showed that
urgency and dysuria were mostly seen with longer stents and thereby
negatively affected the quality of life of patients .43,47
Flank pain seems to be caused as a result of reflux of urine
towards the kidney raises the intra-pelvic pressure that thereby produces
the pain. The pain is not stimulated by the position of the proximal coil
that is in the upper calyx or in the renal pelvis.48
20
Suprapubic pain may be due to a local bladder irritation
caused by the distal coil or it can also be associated complications such
as encrustation or infection. Hematuria may occur due to the surgical
procedure done for the existing disease or due to the stent placement
itself .Incontinence occurs concomitant with episodes of urgency, or
may be due to stent migration crossing the bladder neck into the
proximal urethra hence bypassing the urethral sphincteric mechanism
of continence.34
Moreover all these symptoms can be as a consequence of
associated stent morbidities like urinary tract infection and
encrustation,so their presence should always be ruled out by urinalysis
and definitive imaging.49
ROLE OF ALPHA ADRENERGIC RECEPTORS IN SYMPTOMS
OF THE LOWER URINARY TRACT: 50
Adrenergic receptors were originally divided into αAR and βAR
categories, but application of molecular biological methods has
confirmed nine total AR subtypes: α1a (formerly named α1c), α1b, α1d,
α2a, α2b, α2c, β1, β2, and β3.
21
α1ARs generally mediate their actions through members of the
Gq/11 family of G proteins that stimulate inositol phosphate (membrane
phospholipid) hydrolysis, with each subtype demonstrating different
efficacy of coupling to phosphoinositide hydrolysis: α1a > α1b > α1d. In
addition, α1AR subtypes can be pharmacologically distinguished on the
basis of differential binding to α1-antagonists (blockers) as well as
differential inactivation by the alkylating agent chloroethylclonidine
(CEC).51 In terms of LUTS, α1AR expression in the prostate, urethra,
spinal cord and bladder is important.52
TISSUE DISTRIBUTION OF α1-ADRENOCEPTOR
SUBTYPES 51,55
All 3 α1-AR subtypes exist in a wide range of human
tissues.The α1A-AR subtype shows highest levels of expression in
human liver, followed by slightly lower levels in heart, cerebellum, and
cerebral cortex; the α1B-AR subtype has highest expression in human
spleen, kidney, and fetal brain; α1D-AR has highest levels in the
cerebral cortex and human aorta.
In terms of LUTS, α1-AR expression in prostate, urethra, spinal
cord, and bladder is important. Molecular and contraction studies in
human prostate tissue demonstrate the α1A-AR subtype predominance
22
(70%–100%) in prostate stroma. One tissue important in LUTS is the
urethra. To date, most studies show that all regions of human urethra
(including bladder neck and intra-prostatic urethra) contain only
α1A-ARs. Because of reflex arcs, spinal cord α1-AR expression may be
important in LUTS.52,53
Normal detrusor (bladder smooth muscle tissue) obtained from
surgical patients expresses predominantly α1D-ARs, although other
subtypes are present to a lesser extent. Studies demonstrating increased
α1D-AR expression and function in models of bladder hypertrophy
provide a mechanistic explanation for increased irritability symptoms
associated with LUTS.51
α1-AR antagonists mediate vasodilation in vasculature; therefore,
one of the side effects of treating LUTS with α1-AR antagonists is
hypotension. α1A-ARs predominate in human splanchnic (mesenteric,
splenic, hepatic, and distal omental) arteries.54
α1-Adrenoceptors are found in the human ureter, with highest
density in the distal ureter. α1-Adrenoceptor antagonists dilates the
lumen of the ureter and reduces the spasms by decreasing the peristaltic
frequency and inhibiting the basal tone of the ureter, which may lead to
improvement in stent-related symptoms. 53
23
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Three α1 ARs (α1a, α1b, and α1d) have been cloned with the
use of molecular technologies and have been characterized
pharmacologically. Because the α1a AR subtype predominates in the
smooth muscle of the prostate and the proximal urethra this subtype has
been assumed to be responsible for the dynamic component of
obstruction and the related voiding symptoms.. Interestingly, the relative
expression of the α1 AR sub-types is changed with chronic outlet
obstructive lesions in the rat urinary bladder, with a remarkable increase
in bladder α1d AR expression but a decrease in bladder α1a AR
expression . These findings imply that the α1D AR may be a new
therapeutic target for controlling irritable bladder symptoms. 55
Tamsulosin is A selective α1A- and α1D-adrenoceptor
antagonist, causing relaxation of the smooth muscles in the prostate,
bladder neck and distal ureter. It is generally used for the treatment of
non-malignant enlargement of the prostate, and also there has been
supportive evidence in its use, in the management of distal ureteric
stones.56
The recently developed selective α1d AR antagonist naftopidil
and the selective α1a AR antagonist silodosin are used for the treatment
of lower urinary tract symptoms around the world. Interestingly, the
26
selective α1d AR antagonist naftopidil improves not only voiding
symptoms but also storage symptoms in patients with benign prostatic
hyperplasia . The improvement of storage symptoms such as urgency
and frequency may be assumed to be from the vesical modulation of α1
AR subtypes in chronic urinary obstructive lesions.50
TAMSULOSIN:
Tamsulosin is a benzenesulfonamide. It is an α1 receptor
antagonist with selectivity for α1A and α1D subtypes. The drug is well
absorbed, and has a t1/2 of 5–10 hours, and is extensively metabolized by
Cytochrome P enzymes . Tamsulosin may be administered at a 0.4-mg
starting dose.56,57,58
ADVERSE EFFECTS:
Tamsulosin affects sexual function in men. It can cause males to
experience retrograde ejaculation. Normally, the bladder sphincter
contracts and the ejaculate goes to the urethra, the area of least pressure.
27
In retrograde ejaculation, this sphincter does not function properly.
Nonspecific adverse effects are headache, dizziness, asthenia and
rhinitis. Other important adverse effects are the floppy iris syndrome,
postural hypotension and syncope. 58
Tamsulosin at the recommended dose of 0.4 mg daily is less likely
to cause orthostatic hypotension than the other drugs in this class .
Tamsulosin in occasional cases can cause a drop in blood
pressure, resulting in dizziness or fainting. Other reported side effects
include vertigo, headache, nasal congestion and palpitations.58
SYMPTOM ASSESSMENT TOOLS :
The first study done to objectively evaluate the symptomatology
associated with stents was carried out by Joshi et al. They prospectively
assessed the bother and prevalence of various urinary tract symptoms
caused by ureteral indwelling catheters by means of validated
questionnaires (International Prostatic Symptoms Score, International
Continence Society male questionnaire, Quality of Life questionnaires,
and the Bristol Female Lower Urinary Tract Symptoms questionnaire.
Though they were definite in demonstrating the association of urinary
symptoms due to stents and the negative impact on the quality of life of
28
the patients. The most important impact was by bringing to attention the
need for the development of a stent-specific symptom measuring tool.
With the aim of improving clinical decision making and
practice, they incidentally developed and validated a questionnaire to
specifically address this purpose. The Ureteral Stent Symptom
Questionnaire (USSQ)59 consisted of 38 items which examined
6 sections: pain, voiding symptoms, work performance, sexual
quotient , overall general health, and additional problems.59
29
MATERIALS AND METHODS
This is a prospective study conducted from February 2013 to
January 2014 at Government Stanley Hospital . A total of 180 patients
were enrolled in his study after following the exclusion and inclusion
criteria. They are as follows
INCLUSION CRITERIA:
a) Patients undergoing semirgid ureteroscopy with DJ stenting .
b) Only patients with uncomplicated ureteric calculi.
EXCLUSION CRITERIA:
1. Patients with growth in Urine culture or having symptomatic
urinary tract infection.
2. Patients who may need bilateral stent insertion for acute
obstruction / obstructive uropathy
3. Male patients with history of prostatic enlargement, prostatitis or
prostatic cancer related lower urinary tract symptoms
4. Females with lower urinary tract symptoms related to any form
of urinary incontinence, uterine/cervical/vaginal prolapse, or
obstruction related to malignancy.
30
5. History of chronic or recent α-blocker or analgesic drug use
were excluded.
6. Pregnancy,
7. Bleeding disorders,
8. Patients with concomitant other lower tract pathology like
bladder cancer, bladder outlet obstruction with or without stones,
urethral stricture.
9. Patients with simultaneous renal calculus.
10. Patients who underwent open surgery for ureteric calculi
previously.
Methodology:
These patients were evaluated by taking a detailed history
followed by a complete clinical examination . Relevant past, personal
history and clinical data along with co-morbid factors are noted. Routine
blood investigations along with renal function test including blood urea
and serum creatinine level, urinalysis and urine culture sensitivity were
done and recorded. Further evaluation in the form of X ray KUB , USG
abdomen and pelvis, were done both pre-operatively and
31
post-operatively. Based on this data diagnosis was made and planned for
ureteroscopy and DJ stenting. Anesthetist fitness was obtained for
surgery accordingly. An informed consent and consent for stenting was
obtained from the patient after clearly explaining about the procedure
and the implications. Indication for stent placement in each case was
noted. Patients are given a questionnaire to assess the baseline
symptoms using the IPSS questionnaire along with the quality of life
component of the chart as prescribed by AUA guidelines. Also the pain
component is evaluated by the Visual Analog Pain ScaleTM followed
universally. Scoring is done after adequately explaining about each
component of the chart.
Under spinal anesthesia ,patient was placed in the lithotomy
position with ipsilateral leg lower and straighter to facilitate easy
ureteroscope entry. Cystoscopy was done using 20 Fr sheath . 30 degree
scope. The entire urethra assessed and bladder visualized for any
associated pathology. Both ureteric orifices were visualized and 0.032
inch guide wire passed into the ipsilateral ureter containing the stone.
Then the cystoscope was removed and 8 Fr infant feeding tube was
passed into the bladder. 8/9.8 Fr semirigid ureteroscope was passed into
the ureter under normal saline irrigation and passed proximally up into
the ureter until the calculus is visualized. Patients with intra-operative
32
findings of difficult ureteroscope entry, ureteric stricture, dense stone
impaction, edema and bleeding were excluded from the study. Then
using pneumatic lithotripsy stone is fragmented completely. Following
this patients underwent DJ stenting with 5 Fr/26 cm one end open
silastic DJ stent. Patients who had residual stone fragments that could
not be fragmented at all were exclude from the study. Post-operatively
patients were explained about the presence of DJ stent, and the need to
come for stent removal after 2 weeks (14 days).
A post-operative imaging is done to confirm the position of the
stent. Then the patients are discharged on the 2nd /3rd post operative day
if there is no significant event and are prescribed medicines as per the
group they are allotted to based on the Random number chart.
STUDY DESIGN:
Patients were prospectively randomized by random-number chart
into two groups.
Group A comprised of patients who received Tab. Ciprofloxacin
500mg twice daily and Tab. Paracetamol 500 mg thrice daily for
three days.
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Group B comprised of patients who received Tab Ciprofloxacin 500mg
twice daily, Tab. Paracetamol 500 mg thrice daily for three days and
Tab.Tamsulosin 0.4mg once daily for two weeks (14 days).
URINARY TRACT SYMPTOM ASSESSMENT:
The International Prostate Symptom Score (IPSS)
questionnaire60,61 was used to assess patients’ symptoms on admission as
a, baseline before patient under went the surgery and again reassessed
after two weeks when the patient came for stent removal.
The IPSS questionnaire consists of seven questions, four relating
to voiding (obstructive) symptoms and three to storage(irritative)
symptoms. Responses were graded on a five-point rating scale. The
maximum scores for voiding and storage symptoms are 20 and 15,
respectively; the higher the score, the worse are the symptoms.
QUALITY OF LIFE ASSESSMENT :
Quality of life (QofL) was assessed on admission as a, baseline
before patient under went the surgery and again reassessed after two
weeks when the patient came for stent removal using the QofL section
of the IPSS questionnaire.
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VISUAL ANALOG PAIN SCALE :
Also the pain component is evaluated by the Visual Analog Pain
ScaleTM . on admission as a, baseline before patient under went the
surgery and again reassessed after two weeks when the patient came for
stent removal.
All the scoring is done after adequately explaining about each
component of the chart each time.
They were asked to report to the casualty department in case
of any emergency. A discharge summary was given with clear
instructions and a stent diary was maintained in the department with all
details about patient particulars like address, contact phone number, and
probable date of of stent removal and maintained regularly.
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Stent removal was done under local anesthesia as an outpatient
procedure using 20Fr /30 degree scope.
STATISTICAL ANALYSES :
Data were analysed using χ2 test , Student’s t test, Independent
sample T test and paired sample T test .
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RESULTS
This is a prospective study conducted from February 2013 to
January 2014 at Government Stanley Hospital . A total of 180 patients
were enrolled in this study after following the exclusion and inclusion
criteria.
Patients were prospectively randomized by random-number
chart into two groups.
Group A comprised of patients who received Tab.
Ciprofloxacin 500mg twice daily and Tab. Paracetamol 500 mg thrice
daily for three days.
Group B comprised of patients who received Tab Ciprofloxacin
500mg twice daily, Tab. Paracetamol 500 mg thrice daily for three
days and Tab. Tamsulosin 0.4mg once daily for two weeks (14 days).
The mean age of patients in Group A and was 35.79 with an
age range of 10 to 62 years . The mean age of patients in Group B was
36.62 with an age range of 13 to 64 years.
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1. AGE AND SEX DISTRIBUTION
The mean age of patients in Group A and was 35.79 with an age
range of 10 to 62 years . The mean age of patients in Group B was 36.62
with an age range of 13 to 64 years.
In Group A consisted of 58 men and 32 women whereas Group
B had 54 men and 36 women.
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2. STONE CHARACTERISTICS
In Group A 25 ,12 and 53 patients had upper, mid and lower
ureteric calculus respectively. In Group B 24,10 and 56 patients had
lower ureteric calculus respectively.
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COMPARISON OF BOTH GROUPS AT BASELINE :
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On comparing both the groups A and B based on the symptom
scores assessed at baseline the following observations were made. The
mean IPSS score of group A was 7.68 (SD 2.18) with an irritative score
of 3.32 (SD 0.99) and obstructive score of 4.36 (SD1.39) and in group B
the means of IPSS score, irritative score and obstructive symptom score
were 7.91(SD 1.77), 3.48(SD 1.01) and 4.43 (SD 1.04). The P value of
the above three mean’s compared between these two groups were
0.431for IPSS score,0.298 for irritative score and 0.672 for obstructive
score , indicating that there was not much difference between the two
groups.
The mean visual analog pain scores for group A and B were
4.24 (SD1.04) and 4.31 (SD 1.08). The mean of Quality of Life scores
were 2.89(SD 0.68) and 3.06 (SD 0.084) for group A and B respectively.
Again they indicate that there was no difference in symptoms and bother
between the two groups. So the chosen sample population in both the
groups were the same at baseline since the difference between them
were not statistically significant.
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COMPARISON OF BOTH GROUPS AT STENT REMOVAL :
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On comparing both the groups A and B based on the symptom
scores assessed at stent removal after 2 weeks(14 days) the following
observations were made.
The mean IPSS score of group A was 13.37(SD 2.13) with an
irritative score of 8.82 (SD 1.76) and obstructive score of 4.54(SD 0.75)
and in group B the means of IPSS score, irritative score and obstructive
symptom score were 5.12(SD0.67), 2.34(SD 0.50) and 2.78 (SD 0.70).
The P value of the above three mean’s compared between these two
groups were all <0.001 indicating, that the difference between these two
groups based on these symptom scores were all statistically significant.
The mean visual analog pain scores for group A and B were
5.67(SD0.92) and 3.10(SD 0.70). The mean of Quality of Life scores
were 3.43(SD 0.81) and 2.08 (SD 0.74) for group A and B respectively.
Again both the above observations indicate that the difference in
symptoms and bother between the two groups were statistically
significant. Hence it indicates that patients in group B who received tab.
Tamsulosin 0.4 mg for 2 weeks showed lesser quantum of symptoms
and benefited as compared to those who did not receive it (group A) and
the difference is statistically significant .
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COMPARISION WITHIN THE GROUPS :
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In group A at baseline the mean of IPSS score was
7.68(SD2.177), irritative score was 3.32(SD 0.992), obstructive score
was 4.36(SD 1.393), visual analog scale was 4.24(SD 1.042) and the
quality of life score was 2.89 (SD0.678), but at stent removal the mean
these scores were 13.37 (SD 2.133) for IPSS,8.82 (SD 1.765) for
irritative score, 4.55(SD 0.752) for obstructive score, 5.67 (SD 0.924)
for visual analog scale and 3.43(SD 0.808) for quality of life score.
These P values of the corresponding means for the variables
like IPSS score, irritative score, visual analog pain scale and quality of
life scale were statistically significant (<0.001) indicating that the
among patients who underwent stenting and did not receive tab.
Tamsulosin 0.4 mg the symptom scores at baseline had worsened except
for the obstructive score whose P value was 0.135 and was not
statistically significant.
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In group B at baseline the mean of IPSS score was
7.91(SD1.771), irritative score was 3.48(SD 1.008), obstructive score
was 4.43(SD 1.039), visual analog scale was 4.31 (SD1.077) and the
quality of life score was 3.06 (SD 0.606) , but at stent removal the mean
of these scores were 5.12(SD 0.668) for IPSS, 2.34(SD 0.501) for
irritative score, 2.78 (SD 0.700) for obstructive score, 3.1(SD 0.704) for
visual analog scale and 2.07(SD 0.738) for quality of life score.
The P values of the corresponding means for the variables
like IPSS score, irritative score, obstructive score, visual analog pain
scale and quality of life scale were all statistically significant (<0.001)
indicating that among patients who underwent stenting and received tab.
Tamsulosin 0.4 mg the symptom scores at baseline did not show
worsening of symptoms after stenting at 2 weeks and also showed
considerable improvement in symptom scores over the baseline .
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DISCUSSION
Urolithiasis is one of the oldest and commonest problems
afflicting the urinary tract. In recent times ureteroscopy, is among the
most common endourological procedures performed across the world.
Despite the various genuine indications for stenting, ureteral stents are
observed to be overused in current urology practice.
In a study conducted by Auge and colleagues, among community
and practicing urologists from centers all over the world they reported
that 98% of them would perform ureteroscopic stone surgery as a
routine. Among these, two-thirds of them would place a stent more than
half (>50%) of the time and 13% would always prefer to place a
post-operative stent, even though stent related symptoms and
morbidity were a significant problem faced by patients (98%).
Despite advances and refinements in stent design and
material ,extensive use of ureteral stenting following endourologic
surgeries,is associated with considerable morbidities comprising of
urinary symptoms, pain and a definite impact on quality of life of the
patient. In our study among the group A patients ,the data and the
subsequent observations suggest that stenting has produced significant
(P<0.001) symptoms related to it. Joshi et al and Miyako et al have
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shown that stent related symptoms occur in about more than 80% of the
patients and is a common problem faced by the patient and dealt
routinely by the urologist.
The cause of stent-related symptoms and the mechanisms
involved are not fully understood and it is contemplated that the
involuntary contraction of the bladder secondary to irritation of the
trigone contributes to the bothersome urinary symptoms. In addition,
increased resistance to bladder outlet and pressure generated during
micturition lead to reflux of urine .
Alpha-blockers reduce flank pain by causing a decrease in
the muscle tone of the ureter, trigone of the bladder and prostatic urethra
by means of blocking the α-adrenergic receptors and thereby decreasing
the bladder outlet resistance and the pressure developed during
micturition. In our study it is observed that patients who received Tab.
Tamsulosin 0.4 mg following stenting showed definitely lesser
symptoms overall and also demonstrated a significant reduction in their
baseline bother symptoms. This indicates to the comprehensive effect of
tamsulosin in lower urinary tract symptoms which is due to its action on
α1A and α1D receptors distributed across the lower urinary tract.
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Considering and study and two meta-analyses that were been
recently published , it seems that α-blockers can effectively relieve
stent-related symptoms.
The patients receiving Tamsulosin experienced significant
reductions in the total IPSS, irritative subscore, flank and voiding pains,
and QoL compared with those that did not receive it.
Although all patients had correct stent placement at discharge,
one patient in the tamsulosin group and three patients in the group that
did not receive it complained of severe pain and the stents were
removed much earlier in all the 4 patients (3 in group A and 1 in group
B)and were excluded from the study. Also 5 patients developed
hematuria during the course of the study in the post-operative period
and were excluded from the study.
So stent related morbidity a common problem faced by every
urologist, which puts them through a dilemma, in which case every
scenario has to weighed against the pros and cons. Stenting per se
causes unnecessary increase in cost in the form of extra procedure to
remove it and the cost towards the stent and the cost involved in treating
the complications and the lingering odd risk of forgotten stent which
might present at a later date with a variety of problems like
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encrustation ,renal calculi ,infection ,sepsis and the difficult scenario of
renal failure. At same time in cases where stenting is done for genuine
causes the related symptoms can be treated effectively by α-blockers
like Tamsulosin.
LIMITATIONS OF THE STUDY :
1) We applied stents of same size and length for all patients; however,
some studies have shown that the stent length is directly proportional
with stent-related symptoms , and some studies have shown evidence to
the contrary. Given this point, we used same length (26 cm /5Fr ) stents,
for all the patients.
2) We used the IPSS scoring for evaluation of urinary symptoms, but
Joshi et al. have developed a specific tool for assessing stent-related
symptoms which is named “ureteric stent symptoms questionnaire”
(USSQ). Although, it has been previously implemented, we could not
apply it due to complexity of the variables involved and its validity and
reliability which were not confirmed till date.
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CONCLUSION
 Stenting the ureters following endourologic procedures though being
done routinely is not without its problems. It is most commonly
associated with considerable symptoms, like irritative voiding
symptoms, pain and bother so much, that it affects the quality of life
of the patient significantly.
 The quantum of pain , irritative symptoms and afflicted quality of
life which the patient is put through should be borne in mind and
carefully weighed against the benefits they might provide and the
decision should be individualized in each patient every time.
 In such cases where stenting is being done ,the patient should be
given the benefit of having the stent and at the same time his
symptoms should be alleviated by the judicial use of tablet
tamsulosin 0.4mg once daily for 14 days.
 Stent related morbidity is an entity in itself, and the influence of
α adrenergic receptor blockers like Tamsulosin over the irritative
symptoms is significant due to the distrbution of the α1A and α1D in
the lower tract of the urinary system.
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 Pain produced by stent may range from flank pain to suprapubic
pain to dysuria and the occasional non specific lower abdominal
pain, which affects the quality of life of the patient significantly. The
routine use of non steroidal anti-inflammatory drugs like
paracetamol do not seem have much influence over the lower
urinary tract pain and associated symptoms.
 Definitely, patients those of whom are prescribed non selective α
adrenergic receptor blockers like Tamsulosin ,following
stenting ,seem to benefit significantly because not only did they
experience much lesser symptoms and bother, but they also
improved over their symptoms with which they presented at
admission. This would concur to the explicit influence these group
of α adrenergic receptor blockers have over the lower urinary tract
and gives them a definite role in treating patients afflicted with stent
related morbidity.
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நtக அ²ைவ சிகிvைச ம² ேட}y ெபா¯{திtெகாள
ேவz எ}² ம¯{¢வƫ றினாƫ. எனt சி²நரக
ழாகள ஏபyள அைட~ப}ைன நtகº
ேமெகாz அைட~© ஏபடாமலி¯tக ,எனt ெசயºள
அ²ைவ சிகிvைசய} ஒ¯ பதியாக
ேட}y ெபா¯{திtெகாளº சமத இ|த ேநாைய பறிய
ச|ேதககuகைள நா} ேகyக வளtகினாƫ.இ|த ஆபேரஷ} த}ைம,
பtக ம² ப} வைளºகைள­ ம¯{¢வƫ வளtகினாƫ.
. இ|த ஆவனா எனt, ெபா¢வாக
மற ேநாயாளக¶t கிைடtக ய ந}ைமக எனt
எ{¢ைரtக~பyடன. இ|த ஆº றி{¢, நா} எ¸~பய
வனாtக ம² ச|ேதகuக¶t ம¯{¢வƫ வளtகமாக
பதிலள{தாƫ. இவைற ெதƬ|¢ ெகாzட நா} என¢ ய நிைனºட}
இ|த ஆவ பuேகக என¢ வ¯~ப{தி}ேபƬ யா¯ைடய
நிƫப|த« இலாம எ} ய நிைனºட} இ|த ஆவ பuேகக
என¢ வ¯~ப{ைத ெதƬவ{¢tெகாகிேற}. இ|த ஆº,
எ}§ைடய, ம² எ} ேபா}ற ேநாயாளயƫ நல} க¯திேய
ெசய~பகிற¢ எ}பைத அறி|ததா இத எ}ைன
ஆyபட¢கி}ேற}.
இ|த ஆº றி{¢ «¸ வவரuகைள நா} ேகy
ெப²ளதா´, எ}§ைடய வ¯~ப{தி}ேபƬ பu
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ெகாவதா´, இ¢ றி{¢ எ|த ற «ைறயyைட­ ம¯{¢வƫ
மேதா, ஏைனய ம¯{¢வ ஊழியƫக மேதா, ம¯{¢வமைன மேதா
எ|த நிைலய´ ைவtக மாyேட}. இைதேய எ}§ைடய ஒ~©த
ம² ேவzேகா கதமாக ஏ²tெகா¶மா²
ேகytெகாகிேற}.
ேநாயாளய} ைகெயா~ப
சி²நரக ழாகள அைட~© ஏபடாமலி¯tக அ²ைவ சிகிvைசய}
ஒ¯ பதியாக ேட}y ெபா¯{¢ ேபா¢ ஏப பtக
வைளºகைள டாேலாசி} எ}ற ம¯|தினா ைறtக «­.
ேநாயாளய} ஒ~©த பவ
ஆராvசி நிைலய : அர டா}லி ம¯{¢வமைன,
ெச}ைன 600001
பu ெப²பவƬ} ெபயƫ :
பu ெப²பவƬ} ைகெயா~ப :
பu ெப²பவƫ இதைன ( ) றிtகº
ேமேல றி~பyள ம¯{¢வ ஆவ} வவரuக எனt வளtக~பyட¢.
எ}§ைடய ச|ேதகuகைள ேகyகº, அதகான த|த வளtகuகைள
ெபறº வா~பளtக~பyட¢ .
நா} இ|த ஆவ த}னvைசயாக{தா} பuெப¯கிேர} .எ|த
காரண{தினாேலா எ|த சyடசிtகக¶t உyபடாம நா} இ|த
ஆவ இ¯|¢ வலகிtெகாளலா எ}² அறி|¢ ெகாzேட}.
இ|த ஆº சப|தமாகேவா, இைத சாƫ|த ேம´ ஆº ேம
ெகா¶ ேபா¢ இ|த ஆவ பuெப² ம¯{¢வƫ எ}§ைடய
ம¯{¢வ அறிtைககைள பாƫ~பத எ} அ§மதி ேதைவயைல
என அறி|¢ெகாகிேற}.நா} ஆவ இ¯|¢ வலகிtகிெகாzடா´ இ¢
ெபா¯|¢ என அறி|ேத}.
இ|த ஆவ} ¬ல கிைடt தகவகைள­ , பƬேசாதைன
«ºகைள­, ம² சிகிvைச ெதாடƫபான தகவகைள­
ம¯{¢வƫ ேமெகா¶ ஆவ பய}ப{திtெகாளº அைத
பரƬtகº எ} «¸ மன¢ட} சமதிtகிேற}.
இ|த ஆவ பu ெகாள ஒ~©tெகாகிேற}. எனt ெகாtக~பட
அறிºைரகள} ப நட|¢ ெகாவ¢ட} இ|த ஆைவ ேமெகா¶
ம¯{¢வ அணt உzைம­ட} இ¯~ேப} எ}² உ²தி
அளகி}ேற}. எ} உட நல பாதிtக~பyடாேலா அல¢ எதிƫபாராத,
வழtதிƫtமாறன ேநாtறி ெத}பyடாேலா உடேன அைத
ம¯{¢வ அணt ெத¯வ~ேப} என உ²தி அளtகிேற}.
இ|த ஆவ எனt ர{த, சி²நƫ, எtேர, ேக}, உyபட
அைன{¢ பƬேசாதைனகைள­ ெச¢ ெகாள நா} «¸
மன¢ட} சமதிtகிேற}.
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பuேகபவƬ} ைகெயா~ப........................................ ..................இட.....................ேததி ...........................
கyைடவர ேரைக..................................................................
பuேகபவƬ} ெபயƫ ம² வலாச ...........................................................................................................
...................................................................................................................................................................................................
ஆவாளƬ} ைகெயா~ப........................................................... ..இட........................ ேததி.........................
ஆவாளƬ} ெபயƫ ................................................................
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1 Kali Male 41 1406087 Lt VUJ
Calculi
11 5 6 5 3 15 10 5 7 3
2 Manoharan Male 44 1406507 LT LOWER
URETERIC
CALCULUS
9 4 5 4 2 14 9 5 6 3
3 Pandian Male 47 1405753 Rt lower
uretric
calculus
7 3 4 3 2 13 9 4 6 3
4 Saravanan Male 16 1405320 Lt vuj
calculus
8 3 5 3 2 12 8 4 5 3
5 Jayakumar Male 18 1404059 RT VUJ
CALCULUS
WITH HUN
6 2 4 4 3 10 6 4 5 3
6 Panjalai Female 48 1404097 LT HUN
WITH VUJ
CALCULUS
11 5 6 4 3 16 11 5 7 4
7 Selvi Female 58 1401223 LT MID
URETERIC
CALCULUS
6 3 3 4 3 12 8 4 6 3
8 Bhavani Female 27 1400904 LT vuj
calculus
8 3 5 3 2 13 8 5 6 3
9 Dhatchayani Female 44 1400917 LT LOWER
uretric
calculus
9 4 5 5 3 14 9 5 6 4
10 Anbu Selvi Female 45 54412 Rt UPPER
uretric
calculi with
hun
11 5 6 5 3 18 11 7 6 5
11 Babu Male 37 54011 Lt VUJ calculi 5 2 3 3 3 11 7 4 5 3
12 Sumathy Female 36 52831 Lt LOWER
ureteric
calculi
10 4 6 5 3 16 11 5 6 4
13 Lakshmi Female 37 51130 Rt upper
uretric
calculi
5 2 3 3 2 10 7 3 5 3
14 Sasikumar Male 23 50628 Rt VUJ
calculi
8 3 5 4 2 14 9 5 6 3
15 Stephen Raj Male 23 50024 Rt vuj calculi 7 3 4 4 3 12 8 4 5 4
16 Malathy Female 17 50129 LT LOWER
URETRIC
CALCULI
5 2 3 5 4 10 6 4 4 2
17 Selvakumar Male 34 49236 Rt LOWER
uretric
calculi
6 3 3 4 3 12 8 4 5 3
18 Duraisamy Male 37 48908 Rt vuj calculi 8 4 4 3 3 13 8 5 5 3
19 Jamrath Banu
(a) Banu
Female 48 47537 Rt UPPER
uretric
calculi
12 5 7 6 2 16 11 5 6 5
20 Suresh (a)
Suresh Kumar
Male 34 47469 Rt lower
uretric
calculi
5 2 3 3 3 11 6 5 5 3
21 Vinoth Male 24 46599 LT VUJ
CALCULUS
5 3 2 5 4 12 6 6 5 3
22 Kumar (A)
Prakash
kumar
Male 35 44532 Rt MID
uretric
calculus with
hun
7 3 4 4 3 13 9 4 5 3
23 Ranganagayi Female 60 45090 RT LOWER
URETRIC
CALCULLI
11 5 6 6 4 15 10 5 6 4
24 Rajendran Male 52 43560 Rt LOWER
uretric
calculi
5 3 2 4 3 11 7 4 5 3
25 Jamuna Female 38 43589 Lt lower
uretric
calculus lt
hun
9 4 5 4 3 14 9 5 6 4
26 Sugirtharaj Male 52 43410 Rt vuj calculi 8 3 5 3 3 16 11 5 7 5
27 Janakiraman Male 45 43073 Lt UPPER
uretric
calculi with
hun
6 3 3 4 2 11 6 5 5 3
28 Babu Male 43 42680 Lt vuj calculi 9 3 6 4 4 14 10 4 6 4
29 Balasundaram Male 57 40997 Lt UPPER
uretric
calculi
10 4 6 5 4 16 11 5 7 4
30 Shakila Female 42 40358 LT UPPER
URETRIC
CALCULI
7 3 4 4 3 13 9 4 5 3
31 Ganesan Male 45 30415 Lt LOWER
uretric
calculi/hun
12 5 7 6 4 16 10 6 6 5
32 Madhan Male 24 38156 Rt vuj calculi 9 5 4 4 2 13 9 4 5 4
33 Umapathy Male 48 37342 LT UPPER
uretric
calculi
11 4 7 5 4 15 10 5 6 5
34 Palayam Male 38 37176 Lt mid
uretric
calculi
10 4 6 6 3 16 11 5 6 4
35 Vijayakumar Male 32 37756 Rt vuj calculi 6 3 3 4 2 12 8 4 5 3
36 Vennila Female 30 36647 Rt hun with
upper uretri
calculi
9 4 5 3 2 16 10 6 6 4
37 Sukumari Female 27 35656 Lt mid
uretric
calculi with
hun
7 3 4 3 3 12 8 4 5 3
38 Selvarani Female 30 33097 RT LOWER
URETRIC
CALCULUS
5 2 3 4 2 10 6 4 5 2
39 Sathya Female 20 32072 Lt lower
uretric
calculi
5 3 2 3 3 14 10 4 5 4
40 Mayakrishana
n
Male 55 29203 Rt vuj calculi 9 4 5 5 2 13 9 4 5 3
41 Krishnaveni Female 21 30352 Lt vuj calculi 6 3 3 5 3 17 12 5 7 4
42 Rajesh Male 30 27960 LT HUN
WITH VUJ
CALCULUS
7 2 5 4 3 11 7 4 5 3
43 Jayakumar Male 19 28374 Lt lower
uretric
calculi
5 2 3 5 2 9 5 4 4 2
44 Rajiv Gandhi Male 26 28790 Rt UPPER
uretric
calculi with
hun
6 3 3 4 2 13 9 4 5 3
45 Umamahesh
wari
Female 28 28381 LT HUN
UPPER
URETRIC
CALCULI
6 2 4 3 2 11 7 4 4 3
46 Govindaraj Male 60 27788 Lt hun upper
uretric
calculus
8 3 5 4 3 14 9 5 6 3
47 Unna Malai Female 50 10/13/1
932
RT LOWER
URETRIC
CALCULI
11 4 7 7 4 17 12 5 7 5
48 Dhanalakshmi Female 38 26153 Rt hun
upper
uretric
calculus
9 4 5 5 4 15 10 5 6 3
49 Babu Male 40 25864 Rt upper
uretric
calculi
7 3 4 3 4 13 9 4 5 3
50 Babu Male 24 25226 Lt vuj
calculus
6 3 3 2 3 12 8 4 4 3
51 James Male 28 25059 Lt vuj calculi 11 4 7 5 4 16 11 5 6 5
52 LIVENGSTON Male 44 22689 Rt mid
uretric
calculi
8 4 4 3 3 13 9 4 5 3
53 Prabha Female 23 21481 Rt upper
uretric
calculi
8 3 5 3 2 14 9 5 5 4
54 Saroja Female 55 24186 Rt vuj calculi 9 4 5 6 3 16 11 5 7 4
55 KALIL Male 32 21866 LT UPPER
URETRIC
CALCULI
7 2 5 4 3 13 9 4 5 3
56 MANI Male 40 22254 Rt mid
uretric
calculus
11 5 6 6 4 17 12 5 7 5
57 Datchayani Female 25 21858 Rt UPPER
calculi
8 4 4 3 3 14 9 5 5 3
58 Deivanai Female 35 21732 Lt lower
uretric
calculi
12 5 7 6 3 16 9 7 7 5
59 ANANDHAN Male 45 21859 LT upper
uretric
calculi
8 3 5 4 2 13 7 7 7 3
60 JOHNPAUL Male 23 21875 Lt mid
uretric
calculi
5 2 3 4 3 9 5 4 4 2
61 Tamilarasu Male 32 21851 LT MID
URETRIC
CALCULI
HUN
11 5 6 6 3 18 12 6 8 5
62 Kumar Male 34 20663 Lt mid
uretric
calculus
6 3 3 5 3 10 6 4 5 2
63 MANI Male 50 18912 RT mid
CALCULI/HU
N
5 2 3 4 3 13 8 5 6 3
64 Anjalai Female 45 19964 RT MID
URETRIC
CALCULI
7 3 4 3 2 12 8 4 5 3
65 Geetha Female 28 17745 Lt upper
uretric
calculus
8 4 4 5 3 14 9 5 7 4
66 AKBAR BASHA Male 49 19979 Lt MID
uretric
calculus
11 5 6 6 4 15 10 5 6 4
67 Kurshid
Begam
Female 28 19566 Lt upper
uretric
calculus/HU
N
6 2 4 5 2 10 6 4 6 3
68 Poiyathu Male 41 19575 RT UPPER
URETRIC
CALCULI
9 3 6 4 3 14 9 5 6 4
69 Suresh Male 29 18930 Lt lower
uretric
calculus
7 3 4 5 3 13 9 4 5 3
70 Ravi Male 47 18470 Lt vuj
calculus
11 6 5 6 4 17 12 5 7 4
71 Murugesan Male 37 18472 LT LOWER
URETRIC
CALCULUS
6 3 3 5 3 11 6 4 6 3
72 Ilayamurugan Male 37 17009 Lt upper
uretric
calculus /
hun
4 2 2 4 3 10 6 4 5 3
73 ELUMALAI Male 31 15792 Rt VUJ
CALCULUS
5 2 3 5 2 11 7 4 4 2
74 Abdul Wahid Male 62 13809 LT VUJ
CALCULUS
WITH HUN
8 3 5 3 3 13 9 4 6 3
75 Sumathy Female 36 15087 Rt VUJ
CALCULI
WITH HUN
7 3 4 3 2 14 10 4 6 3
76 Balaji Male 26 14088 RT UPPER
URETRIC
CALCULUS
5 3 2 4 3 11 7 4 4 3
77 Tharunesh Male 13 13588 Rt VUJ
CALCULI
WITH HUN
4 2 2 3 3 10 6 4 5 2
78 Shankari female 10 13694 RT UPPER
URETRIC
CALCULUS
6 2 4 4 3 13 9 4 5 3
79 Murthy Male 30 13501 RT UPPER
URETRIC
CALCULUS
HUN
5 2 3 3 2 14 10 4 7 4
80 Anjali Female 47 13459 Rt lower
uretric
calculi
10 4 6 5 4 14 10 4 6 3
81 David Male 33 11318 LT VUJ
CALCULUS
WITH HUN
6 3 3 4 3 13 9 4 6 3
82 Indian Male 14 11449 Lt VUJ
Calculi
9 5 4 6 3 14 10 4 6 4
83 Ameena (A)
Sumeena
Male 24 9799 RT lower
uretric
calculus
7 3 4 4 2 13 9 4 5 3
84 Nirmala Female 35 8800 Rt upper
uretric
calculus
HUN
10 4 6 5 4 15 10 5 7 4
85 Pursothaman Male 32 8827 Rt VUJ
CALCULI
7 3 4 3 2 16 11 5 7 5
86 Rajasekar Male 27 8284 Lt VUJ
calculus
8 4 4 4 3 14 10 4 7 4
87 Senthil Male 26 6034 Rt HUN/
lower uretric
calculus
5 2 3 3 3 13 9 4 6 3
88 Vijaya Kumar Male 26 5683 Lt VUJ calculi 6 3 3 4 2 12 8 4 4 3
89 Mohana Valli Female 56 3944 RT LOWER
URETRIC
CALCULI
11 4 7 5 3 15 11 4 6 4
90 Annamalai Male 39 4244 Lt VUJ calculi 6 3 3 4 3 14 10 4 7 3
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1 Venkatesan Male 28 1406889 Rt upper uretric calculus
with hun
8 4 4 4 3 5 2 3 3 3
2 Pavithra Female 48 1402875 Rt lower uretric calculus 7 3 4 4 2 5 2 3 3 2
3 Mahesh Male 28 1405748 Lt LOWER uretric
calculus
9 4 5 5 3 5 2 3 4 2
4 Bhuvaneshwari Female 42 1404087 Rt UPPER ureteric
calculus
10 5 5 6 3 5 2 3 5 2
5 Saravanan Male 28 1404760 Rt vuj calculus 13 8 5 6 4 5 3 2 4 2
6 Rahamath
Nisha
Female 38 1404066 Lt LOWER uretric
calculus
9 4 5 5 3 6 2 4 4 1
7 Raja Male 41 1403479 Rt MID uretric
calculus
6 3 3 3 3 5 2 3 3 3
8 Karthik male 21 1402440 Lt lower uretric calculus
with HUN
7 3 4 3 3 6 2 4 3 1
9 Dhinakaran Male 27 55586 lt upper ureteric calculi 10 5 5 6 4 5 2 3 4 2
10 Anandhi Female 53 51464 RT upper URETRIC
CALCULI
9 4 5 5 3 6 2 4 4 2
11 Sargunam Female 24 53419 Lt upper ureteric calculi 5 3 2 3 2 5 2 3 3 2
12 Mohana
Sundari
Female 34 51546 RT LOWER URETRIC
CALCULI
7 3 4 4 3 6 3 3 4 3
13 Tamilarasu Male 27 51110 LT hun with lower
uretric calculi
9 5 4 5 3 6 2 4 4 2
14 Muthusamy Male 55 45240 RT upper uretric
calculus
7 3 4 4 3 5 2 3 3 3
15 Munusamy Male 45 50582 Rt LOWER uretric
calculi with hun
8 4 4 4 3 6 2 4 3 1
16 Padma Female 64 49213 Lt lower uretric calculi/
hun
5 3 2 3 2 5 2 3 2 2
17 Palayam Male 60 49217 Lt LOWER uretreic
calculi
7 3 4 3 3 6 2 4 2 3
18 Mohammed
Ali jinna (a)
Jinna
Male 36 48236 Lt upper ureteric calculi 6 3 3 3 3 6 3 3 3 2
19 Sundar (A)
Sundar
periyanayagaraj
Male 34 47586 Rt MID uretric calculi 8 4 4 3 3 5 2 3 2 3
20 Annamalai Male 54 46704 RT LOWER URETRIC
CALCULI
11 5 6 5 4 5 3 2 3 1
21 Samundeeswari Female 32 46613 LT VUJ CALCULUS 6 3 3 2 2 6 2 4 2 1
22 Sneha (a)
Sneha Jenifer
Female 17 45103 RT VUJ CALCULI 9 4 5 5 3 6 3 3 3 2
23 Munusamy Male 29 44578 Rt hun LOWER uretri
calculi
8 3 5 5 3 7 2 5 4 2
24 Jayakumar Male 19 41180 Rt LOWER uretric
calculi
7 3 4 4 3 6 2 4 3 3
25 Sarala Female 34 41367 Lt UPPER uretric
calculi / hun
8 4 4 3 3 5 2 3 3 1
26 Anandan Male 36 42673 Lt vuj calculus WITH
HUN
11 5 6 7 4 5 3 2 5 2
27 Arumugam Male 46 42711 Lt vuj calculi
hydronephrosis
6 3 3 3 2 4 2 2 2 2
28 Sami Durai Male 24 41409 Lt uretric calculi 7 3 4 3 3 5 2 3 2 2
29 Elumalai Male 43 40991 RT UPPER URETER
CALCULUS
9 4 5 5 3 6 3 3 4 1
30 Karpagam Female 34 39739 Lt LOWER uretric
calculi
7 3 4 5 3 4 2 2 3 3
31 Vennila Female 45 38771 Lt mid uretric calculi
with hun
6 2 4 3 3 5 2 3 2 1
32 Boopalan Male 33 37575 Rt lower uretric calculi 9 5 4 5 3 6 2 4 4 2
33 Nirmala Bai Female 48 37352 RT VUJ CALCULUS 9 4 5 4 3 6 3 3 3 1
34 Subramani Male 38 37056 Lt upper uretric calculi 8 3 5 3 3 5 2 3 3 2
35 Kamalakannan Male 33 37024 Lt mid uretric calculi 9 4 5 4 3 4 2 2 3 1
36 Malliga Female 55 35856 Rt LOWER uretric
calculi
8 3 5 4 2 4 2 2 2 2
37 Pachiammal Female 27 33832 Lt UPPER uretric
calculi / hun
7 3 4 3 2 6 4 2 2 1
38 Sundarakumar
(a) Chandra
Kumar
Male 41 33092 Rt lower uretric calculus 7 3 4 4 2 5 2 3 3 2
39 Revathy Female 52 31020 Lt lower uretric calculi 6 2 4 2 2 5 2 3 2 2
40 Manikandan Male 31 35061 Rt vuj calculi 9 4 5 4 3 4 2 2 2 3
41 Raman Male 53 27972 Lt vuj calculi/ hun 10 5 5 6 4 5 3 2 4 2
42 Surya Male 13 28577 RT LOWER hun 7 3 4 4 3 6 3 3 3 3
43 Kamaljee Male 24 28018 LT vuj calculi 6 2 4 4 3 5 2 3 3 1
44 Ambika Female 34 28578 RT VUJ CALCULUS 9 3 6 5 3 6 3 3 4 2
45 Deepa Female 28 2874 Lt HUN upper uretric
calculus
7 3 4 4 3 5 2 3 3 2
46 Nagalingam Male 31 27409 Lt vuj calculi 8 4 4 3 4 5 3 2 3 3
47 Gowri Female 30 26930 Rt lower uretric calculus 9 4 5 5 3 5 2 3 4 1
48 Rajamani Male 27 26358 Lt Hun/ uppper uretric
calculi
9 3 6 4 3 4 2 2 3 2
49 Kannan Male 49 25110 Lt hun/mid uretric
calculus
7 2 5 4 3 6 3 3 3 2
50 Valarmathi Female 37 240808 Rt vuj calculi 5 2 3 2 2 5 2 3 2 1
51 Padma Female 40 23006 Rt vuj calculi 9 3 6 5 3 6 2 4 3 3
52 Suresh Male 28 22708 LT UPPER URETERIC
CALCULI
7 3 4 4 3 6 3 3 3 3
53 Ragini Female 30 23448 LT UPPER URETRIC
CALCULUS
8 3 5 5 4 5 2 3 3 1
54 Senthilkumar Male 32 21558 Rt VUJ CALCULI 10 5 5 6 4 5 3 2 4 3
55 Padmanaban male 44 22931 Rt lower uretric calculus 7 3 4 4 3 5 2 3 3 2
56 Ellaiyan Male 38 22746 Rt upper uretric calculi 9 4 5 5 3 5 3 2 3 2
57 Thangavel Male 60 21727 Lt upper uretric calculi 8 4 4 4 2 6 2 4 3 1
58 Ramya Female 18 22317 Rt lower uretric calculi 6 3 3 3 3 5 2 3 3 3
59 SARAVANAN Male 40 21872 Lt mid uretric calcali 9 4 5 5 3 5 3 2 3 2
60 Chitra Female 24 21711 Rt mid uretric calculi 5 3 2 4 2 5 2 3 2 2
61 Rajeshwari Female 45 21563 RT UPPER URETRIC
CALCULUS
7 3 4 3 4 5 3 2 2 1
62 Tamil Selvan male 35 20886 RT VUJ CALCULI 9 4 5 5 4 5 2 3 3 3
63 Muthulakshmi Female 36 20010 LT UPPER URETRIC
CALCULUS
8 3 5 4 3 6 3 3 3 2
64 Akbar Ali Male 36 20008 Lt upper uretric calculus 7 3 4 4 2 4 2 2 4 2
65 Sumathi Female 39 20001 Rt VUJ CALCULI 8 3 5 4 3 5 2 3 3 3
66 Menaga Female 35 19262 LT HUN VUJ CALCULUS 9 3 6 5 3 5 2 3 3 1
67 Sangamma Male 37 19568 RT HUN MID URETRIC
CALCULUS
11 4 7 6 4 5 3 2 4 2
68 Mohan Male 23 19216 Rt VUJ CALCULUS/HUN 8 3 5 5 3 5 2 3 4 3
69 Rafiq Male 29 18319 LT mid urethra
calculus
7 3 4 4 3 5 3 2 3 3
70 Suresh Male 37 17786 LT MID URETRIC
CALCULUS
12 5 7 6 4 4 2 2 3 2
71 Govindaraj Male 31 18422 Rt upper uretric calculus
/HUN
6 2 4 5 4 5 2 3 3 1
72 Ayyanar Male 25 15293 Rt VUJ CALCULUS 7 3 4 4 3 4 2 2 2 3
73 Kumar Male 45 15975 Rt LOWER uretric
calculus
5 2 3 3 3 5 3 2 2 1
74 Ramesh Male 28 15133 RT hun with upper
uretric calculus
7 3 4 5 2 6 3 3 3 2
75 Kanagaman Female 48 15481 LT HUN VUJ CALCULUS 7 3 4 4 4 5 2 3 3 3
76 Kalai Selvi Female 43 14588 RT VUJ CALCULUS/HUN 6 2 4 4 3 4 2 2 3 2
77 Selva male 40 13644 Rt lower uretric calculi 6 3 3 5 3 4 2 2 3 2
78 Chandar (A)
Sundar
Male 29 13038 Rt Lower uretric
calculus
6 2 4 5 3 5 2 3 3 3
79 Rajan(A)
Rasamuthu
Male 21 13021 Lt lower uretric calculus
with HUN
11 5 6 6 4 5 3 2 4 2
80 Manimegalai Female 38 13072 Lt lower uretric calculi 7 3 4 4 4 5 2 3 3 3
81 Raja Sekar Male 41 11450 Rt upper uretric calculi 6 3 3 5 3 5 3 2 4 2
82 Kamala Female 56 11453 RT LOWER URETRIC
CALCALUS
11 5 6 6 4 4 2 2 4 3
83 Velayutham Male 57 9384 Lt VUJ CALCULI 7 3 4 5 3 5 3 2 3 3
84 Tamim Ansar Male 27 9250 Rt VUJ CALCULI WITH RT
HUN
7 3 4 3 3 5 2 3 3 2
85 Poppy Mary Female 43 7182 RT VUJ CALCULUS 11 5 6 6 4 5 3 2 4 2
86 Kamala Female 35 7082 Rt upper urectric calculi 9 4 5 4 3 5 3 2 3 3
87 Vasudevan Male 38 5659 LT UPPER URETRIC
CALCULI
5 2 3 4 3 4 2 2 3 1
88 Mathi Male 47 4959 Lt VUJ Calculi 10 5 5 6 3 5 2 3 3 3
89 Sulochana Female 35 3919 Rt VUJ CALUCULI 12 5 7 6 4 5 3 2 3 2
90 Jothi female 33 3786 Lt lower uretric calculi 8 3 5 4 3 4 2 2 3 3
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